Affiliation: University of California
- The antiretroviral efficacy of highly active antiretroviral therapy and plasma nevirapine concentrations in HIV-TB co-infected Indian patients receiving rifampicin based antituberculosis treatmentSanjeev Sinha
Department of Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India
AIDS Res Ther 8:41. 2011..abstract:..
- Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328)Ronald J Bosch
Harvard School of Public Health, Boston MA, USA
AIDS Res Ther 7:30. 2010..In A5051, 53 patients from A328 who had previously received IL-2 were allowed to continue IL-2 for an additional 80 weeks; 27 patients who had received ART alone received IL-2 for 80 weeks...
- Prevention of bacterial infections in patients with advanced HIV infectionR Mitsuyasu
Center for Clinical AIDS Research and Education, University of California, Los Angeles 90095 1793, USA
AIDS 13:S19-23. 1999..No unexpected or new adverse events were observed and there were no differences in plasma HIV-1 RNA levels between the groups...
- The potential role of interleukin-2 in HIVR T Mitsuyasu
UCLA Center for Clinical AIDS Research and Education, University of California, Los Angeles 90095 1793, USA
AIDS 15:S22-7. 2001..Further evaluation of the clinical efficacy of IL-2 in HIV-infected patients is expected to provide important information on the utility of recombinant human IL-2 in HIV disease...
- Immune therapy: non-highly active antiretroviral therapy management of human immunodeficiency virus-infected patientsRonald Mitsuyasu
University of California, Los Angeles, CARE Center, Los Angeles, California 90095 1793, USA
J Infect Dis 185:S115-22. 2002....
- Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cellsRonald T Mitsuyasu
Center for Clinical AIDS Research and Education, University of California Los Angeles, 9911 West Pico Boulevard, Suite 980, Los Angeles, California 90035, USA
Nat Med 15:285-92. 2009..This study indicates that cell-delivered gene transfer is safe and biologically active in individuals with HIV and can be developed as a conventional therapeutic product...
- Open-label phase I study of combination therapy with zidovudine and interferon-beta in patients with AIDS-related Kaposi's sarcoma: AIDS Clinical Trials Group Protocol 057S Miles
Division of Hematology Oncology, UCLA Clinical AIDS Research and Education Center, UCLA School of Medicine, USA
Cytokines Cell Mol Ther 4:17-23. 1998..Further studies of this agent should be in the context of four-drug antiretroviral regimens where viral suppression is greatest and any antitumor activity of IFN-beta may be observed...
- Gene therapy for the treatment of AIDS: animal models and human clinical experienceR G Amado
Division of Hematology Oncology, UCLA School of Medicine, 11 964 Factor Building, Los Angeles, CA 90095, USA
Front Biosci 4:D468-75. 1999..Herein, we review recent advances in transduction methods, data from in vivo preclinical studies in relevant animal models, and emerging results derived from pilot clinical gene therapy studies...
- Update on the pathogenesis and treatment of Kaposi sarcomaR T Mitsuyasu
Division of Hematology Oncology, UCLA School of Medicine, UCLA Center for Clinical AIDS Research and Education, Los Angeles, California 90095 1793, USA
Curr Opin Oncol 12:174-80. 2000..In this review, recent advances in our understanding of the pathogenesis of KS are highlighted and a brief overview of current approaches to the treatment of this tumor is provided...
- The effect of zidovudine treatment on serum neopterin and beta 2-microglobulin levels in mildly symptomatic, HIV type 1 seropositive individualsH Z Bass
Center for Interdisciplinary Research in Immunology and Disease, Department of Medicine, University of California, Los Angeles
J Acquir Immune Defic Syndr 5:215-21. 1992..Subjects with greater reductions of serum neopterin or beta 2M tended to maintain lower levels of these markers with continued zidovudine administration.(ABSTRACT TRUNCATED AT 250 WORDS)..
- Anemia in HIV infection: clinical impact and evidence-based management strategiesPaul A Volberding
University of California, San Francisco, CA, USA
Clin Infect Dis 38:1454-63. 2004....
- A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024)J Michael Kilby
University of Alabama at Birmingham, Birmingham, AL 35294 2050, USA
J Infect Dis 194:1672-6. 2006..Significant changes were not detected for HIV-specific lymphoproliferative responses in any arm. This exploratory protocol provides useful clinical data for future therapeutic immunization trial design...
- The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328Ronald Mitsuyasu
Department of Internal Medicine, University of California Los Angeles, USA
Arch Intern Med 167:597-605. 2007..Interleukin 2 (IL-2) administration increases CD4 counts in persons with higher counts. This study investigated persons with moderately advanced human immunodeficiency virus infection receiving highly active antiretroviral therapy (HAART)...
- Interleukin-2 Increases CD4+ lymphocyte numbers but does not enhance responses to immunization: results of A5046sHernan Valdez
Case Western Reserve University and University Hospitals of Cleveland, Ohio 44106, USA
J Infect Dis 187:320-5. 2003..Despite dramatic increases in CD4(+) lymphocyte counts, IL-2 did not enhance immunization responses...
- Differential effect of interleukin-2 treatment on primary and secondary immunizations in HIV infected individualsHaydar Kuekrek
Department of Pathology, Case Western Reserve University and University Hospitals of Cleveland, Cleveland, Ohio 44116, USA
AIDS 19:1967-74. 2005..As interleukin (IL)-2 therapy increases CD4 cell counts in HIV infected subjects, it emerged as a candidate for the partial restoration of immune competence in this disease...
- Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2Beverly E Sha
Section of Infectious Diseases, Department of Medicine, Rush Medical College, Chicago, Illinois 60612 3833, USA
AIDS Res Hum Retroviruses 18:661-5. 2002..Pretreatment with etanercept may blunt activation of IL-6 and CRP expression induced by rhIL-2. The safety and utility of etanercept in HIV-infected persons should be explored further...